For the quarter ended March 2024, Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $3.82 billion, up 4.3% over the same period last year. EPS came in at $0.48, compared to $0.40 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $3.7 billion, representing a surprise of +3.25%. The company delivered an EPS surprise of -5.88%, with the consensus EPS estimate being $0.51.While investors closely watch year-over-year changes in headline numbers -- revenue and e ...

Teva Pharmaceutical Industries Ltd. First Quarter 2024 Results This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors ...

Exhibit 99.1 For an accessible version of this Press Release, please visit www.tevapharm.com TEVA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND REAFFIRMS 2024 FINANCIAL OUTLOOK • Generics business and AUSTEDO® growth lead Q1 2024 performance. • Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. • Generics business growth across all regions – increased by 9% in local currency terms globally, compared to Q1 2023. • AUSTEDO – continued growth, up 67% (in ...

SHANGHAI & TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Investments Singapore Pte Ltd (TPIS), a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Jiangsu Nhwa Pharmaceutical Co., Ltd (“Nhwa”) today announced it formed a partnership for the marketing and distribution of Teva’s AUSTEDO (deutetrabenazine) for the treatment of neurodegenerative and movement disorders - chorea associated with Huntington’s disease (HD) and tardive dyskinesia (TD) in adults. The partnership inte ...

Key PointsTeva Pharmaceuticals is a global generic drug maker that is getting ready to form a monthly breakout of its 5-year rectangle range.Teva was upgraded to an Outperform rating by Piper Sandler with a $19 price target.Teva beats its recent Q4 2023 EPS estimates by 23 cents as revenue rose 15% YoY as shares traded at just 5.6X forward earnings.5 stocks we like better than Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries Ltd. NYSE: TEVA is a global pharmaceutical company in the medical secto ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel Not Applica ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q4 2023 Earnings Conference Call January 31, 2024 8:00 AM ET Â Company Participants Richard Francis - President, Chief Executive Officer Eric Hughes - Executive Vice President, Global R&D, Chief Medical Officer Eli Kalif - Executive Vice President, Chief Financial Officer Ran Meir - Head of Investor Relations Conference Call Participants Glen Santangelo - Jefferies Ash Verma - UBS Jason Gerberry - Bank of America Umer Raffat - Evercore David Amsellem - Pipe ...

For the quarter ended December 2023, Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $4.46 billion, up 14.8% over the same period last year. EPS came in at $1.00, compared to $0.71 in the year-ago quarter.The reported revenue represents a surprise of +12.36% over the Zacks Consensus Estimate of $3.97 billion. With the consensus EPS estimate being $0.75, the EPS surprise was +33.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2023. Q4 2023 and Full Year 2023 Highlights:   Q4 2023 FY 2023 Revenues   $4.5 billion $15.8 billion GAAP diluted earnings (loss) per share   $0.41 $(0.50) Non-GAAP diluted EPS   $1.00 $2.56 Cash flow generated from operating activities   $1,184 million $1,368 million ...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva announced today its intention to divest its active-pharmaceutical ingredient (API) business, or "TAPI". TAPI is a global leader in the small-molecule API industry, with approximately 4,300 employees worldwide. The intent to divest “TAPI” will allow Teva to maximize current and potential revenue streams, focusing on capital reallocation towards growth and innovation, and to better serve patients. The intended divestiture is expected to create additional value for Te ...